Cerulean Pharma reported $51.67M in Cash and Equivalent for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamis Pharmaceuticals ADMP:US 17.77M 5.45M
Agile Therapeutics AGRX:US $ 3.74M 15.4M
Arrowhead Research ARWR:US $ 86.41M 5.18M
Bayer BAYN:GR € 5785M 1221M
Brainstorm Cell Therapeutics BCLI:US $ 15.15M 3.7M
Cerulean Pharma CERU:US $ 51.67M 6.1M
Immunogen IMGN:US $ 437.66M 41.09M
Merk MRK:US $ 8556M 460M
Nektar Therapeutics NKTR:US $ 25.22M 28.8M
Perrigo Ordinary Shares PRGO:US $ 1965.5M 100.6M
Seattle Genetics SGEN:US $ 261M 163.84M
YTE INCY:US $ 2256.76M 199.32M